Put companies on watchlist
Implenia AG
ISIN: CH0023868554
WKN: A0JEGJ
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Implenia AG · ISIN: CH0023868554 · EQS - adhoc news (121 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 1465565
18 October 2022 07:00AM

Implenia wins order for large, complex new laboratory project at University of Basel


Implenia AG / Key word(s): Incoming Orders
Implenia wins order for large, complex new laboratory project at University of Basel

18-Oct-2022 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

New laboratory for University of Basel’s Department of Biomedicine | Latest project in research and health sector | Contract worth over CHF 250 million | BIM and Lean Construction used for planning and execution 

Glattpark (Opfikon), 18 October 2022 – The University of Basel has contracted Implenia Division Buildings to build a new laboratory complex for its Department of Biomedicine. 

The Department of Biomedicine (DBM) at the University of Basel is bringing all the experimental laboratory research done by the medical faculty together in this latest new-build. Located on the life sciences campus at the Schällemätteli site in Basel, the new building will house an optimal combination of research, teaching and applied medicine in a single location.

Implenia, in the role of total contractor, won the contract thanks to its impressive team of experts as well as to its many years of experience and proven competence across similar laboratory and healthcare building projects. Furthermore, as the leading Swiss construction and real estate service provider, Implenia can supply the essential civil engineering, construction and other skills from a single source. The contract is worth over CHF 250 million and includes execution planning, construction and commissioning of the building. The project starts this month with an optimisation phase and is expected to last until mid-2028. The complex should open for operations in 2031.
A floor area of approx. 37,000 m2 spread over three basements, a ground floor and eight upper floors, provides space for laboratories, offices and seminar rooms. Planning for the building is based on the Minergie standard. In addition to high technical and hygiene standards, the building’s flexibility is also very important for research. Building Information Modeling (BIM) methods are being used for the planning and construction of the new laboratory complex. These include integrated planning using models from all the specialist disciplines, model coordination and testing with digital tools, and integration of user requirements using Roombook and virtual reality (VR). Digital Lean Construction (e.g. LCM Digital) is being used to schedule service packages, show dependencies, reduce the complexity of work steps and carry out quality and deadline control. 
André Wyss, CEO of Implenia, is delighted with the new order: “This large and complex laboratory construction project is right in line with Implenia’s strategy. We would like to thank the University of Basel for its trust and look forward to building the new laboratory complex together. In recent years, Division Buildings has completed several interesting projects involving the planning and construction of buildings for research, education and healthcare. Our capabilities have evolved accordingly. These growth areas within the Swiss real estate sector are, and will remain, very important to Implenia’s work.”

New laboratory building for the University of Basel’s Department of Biomedicine (image: ©Burckhardt+Partner).

Contact for media:
Corporate Communications, T +41 58 474 74 77, communication@implenia.com 

 

Contact for Investors and Analysts:
Investor Relations, T +41 58 474 35 04, ir@implenia.com 

Dates for investors: 
1 November 2022: Capital Markets Day  
1 March 2023: Annual results 2022, Analysts and Media Conference 
28 March 2023: Annual General Meeting

As Switzerland’s leading construction and real estate service provider, Implenia develops and builds homes, workplaces and infrastructure for future generations in Switzerland and Germany. It also offers tunnelling and related infrastructure projects in further markets. Formed in 2006, the company can look back on around 150 years of construction tradition. The company brings together the know-how of its highly skilled development, planning and execution units under the umbrella of an integrated leading multinational construction and real estate service provider. With its broad offering and the expertise of its specialists, the Group realises large, complex projects and provides client-centric support across the entire life cycle of a building or structure. It focuses on client needs and on striking a sustainable balance between commercial success and social and environmental responsibility. Implenia, with its headquarters in Opfikon near Zurich, employs more than 7,700 people across Europe and posted revenue of CHF 3.8 billion in 2021. The company is listed on the SIX Swiss Exchange (IMPN, CH0023868554). More information can be found at implenia.com.



End of Inside Information
Language: English
Company: Implenia AG
Industriestrasse 24
8305 Dietlikon
Switzerland
Phone: +41 58 474 74 74
E-mail: info@implenia.com
Internet: www.implenia.com
ISIN: CH0023868554
Valor: A0JEGJ
Listed: SIX Swiss Exchange
EQS News ID: 1465565

 
End of Announcement EQS News Service

1465565  18-Oct-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1465565&application_name=news&site_id=boersengefluester_html
Visual performance / price development - Implenia AG
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.